Weight

The ones that actually move the scale.

GLP-1s broke the internet and rewired medicine in the process. Semaglutide, tirzepatide, and the newer triple agonists — this category has the most clinical data, the most mainstream attention, and the most people pretending they 'just started hiking.' The good news: they genuinely work. The less-good news: dosing matters, the nausea is real, and you need to know what you're signing up for before you start.

Top Peptides for Weight

• Tirzepatide (relevance: 96%) — Dual GLP-1/GIP agonist that beat semaglutide head-to-head. ~22% body weight loss in SURMOUNT trials. Currently the best thing available if the scale is the scoreboard.
• Semaglutide (relevance: 94%) — The one that started all of this. FDA-approved, enormous safety dataset, ~15% weight loss. Still the most prescribed and most studied. Your doctor's actually heard of this one.
• Retatrutide (relevance: 85%) — Triple agonist — GLP-1, GIP, and glucagon. Phase 2 hit ~24% weight loss. Not approved yet but the data is making people very impatient.
• Tesamorelin (relevance: 68%) — FDA-approved GHRH analog that goes after visceral fat specifically. Not a GLP-1 — completely different mechanism via growth hormone. Different tool for a different problem.
• Survodutide (relevance: 62%) — Dual glucagon/GLP-1 agonist pulling double duty on weight loss AND fatty liver. Still in trials, but if you've got both problems, this one's worth tracking.
• AOD-9604 (relevance: 45%) — HGH fragment marketed for fat loss. Evidence is thinner than the GLP-1s and the results are more modest. Some people swear by it. The data shrugs.

Common Questions

• Semaglutide or tirzepatide — which one should I pick?
• How bad is the nausea really?
• Do I gain the weight back when I stop?
• What's the difference between compounded and brand-name?
• How do I titrate up without feeling terrible?

Related Comparisons

• AOD-9604 vs Semaglutide — The growth hormone fragment that promised fat loss vs the GLP-1 that actually delivers it.
• CJC-1295/Ipamorelin vs Tesamorelin — Two approaches to growth hormone secretion. One's a broad anti-aging stack, the other targets belly fat with FDA backing.
• Semaglutide vs Retatrutide — The current king versus the triple-agonist that might dethrone it. One's approved, one's not.
• Semaglutide vs Tirzepatide — The two GLP-1 heavyweights, head to head. Same family, different firepower.
• Tirzepatide vs Retatrutide — Dual agonist vs triple agonist. Both from Eli Lilly. One's available, one could be the endgame.

← Browse all peptides

These statements have not been evaluated by the FDA. This content is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any protocol.

vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify